Viatris, Biocon Launch Biosimilar Products Interchangeable For LANTUS - Quick Facts
(RTTNews) - Viatris Inc. (VTRS) and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE injection, a branded product, and Insulin Glargine injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. The companies noted that the biosimilar products are interchangeable for the reference brand, LANTUS.
Viatris said the currently marketed non-interchangeable SEMGLEE is anticipated to be phased out by the end of the calendar year 2021.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.